These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19169757)

  • 1. Important matters to identify robust markers for metastasis and recurrence in solid cancer.
    Mimori K; Iwatsuki M; Yokobori T; Mori M
    Ann Surg Oncol; 2009 Apr; 16(4):1070-1. PubMed ID: 19169757
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating cancer cells: could they be used in the clinic as recurrence markers for gastric and colorectal cancer?
    Hanisch E; Hottenrott C; Roukos DH
    Ann Surg Oncol; 2009 Mar; 16(3):778-9; author reply 780-2. PubMed ID: 19116754
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges in developing robust genetic markers and targets to predict and prevent distant and peritoneal recurrence in gastric cancer.
    Ziogas D; Roukos DH
    Ann Surg Oncol; 2009 Apr; 16(4):1068-9. PubMed ID: 19184235
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Berney DM
    Eur Urol; 2009 May; 55(5):1134. PubMed ID: 18585844
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    van der Poel HG
    Eur Urol; 2009 May; 55(5):1133-4. PubMed ID: 18585847
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tumor markers in the diagnosis of solid tumors].
    Koch OM
    Internist (Berl); 1992 Aug; 33(8):W79-86. PubMed ID: 1526714
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tumor markers--how they should be applied].
    Stieber P; Heinemann V; Schalhorn A
    MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
    Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
    Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up care of cancer survivors.
    Galassi A
    Lippincotts Prim Care Pract; 2000; 4(4):359-70; quiz 371-3. PubMed ID: 11261113
    [No Abstract]   [Full Text] [Related]  

  • 10. [Computerized evaluation of the informativeness of radioimmunologic tests in the diagnosis of stomach cancer].
    Ozherel'ev AS; Tkacheva GA; Glazkova TG
    Med Radiol (Mosk); 1987 Nov; 32(11):29-31. PubMed ID: 3683119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosticating gastric cancer.
    So JB; Yeoh KG
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1478-9. PubMed ID: 19743992
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum 3'-sulfo-Lea indication of gastric cancer metastasis.
    Zheng J; Bao WQ; Sheng WQ; Guo L; Zhang HL; Wu LH; Wu XZ
    Clin Chim Acta; 2009 Jul; 405(1-2):119-26. PubMed ID: 19394320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers in the control of the treatment of gastrointestinal carcinomas].
    Lorenzi M; Inaudi P; Caldarone R; Garzi A; Lorenzini L
    Minerva Chir; 1987 Oct; 42(20):1621-4. PubMed ID: 3683923
    [No Abstract]   [Full Text] [Related]  

  • 14. [Posibilities for using high-resolution nuclear magnetic resonance spectroscopy and histotomography in tumors and metastases].
    Haferkamp O
    Internist (Berl); 1988 Jan; 29(1):34-42. PubMed ID: 3280510
    [No Abstract]   [Full Text] [Related]  

  • 15. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
    Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
    Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection.
    Choi SB; Park SW; Kim KS; Choi JS; Lee WJ
    J Surg Oncol; 2009 May; 99(6):335-42. PubMed ID: 19226533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
    Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
    Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma antigen-1 mRNA combined with alpha-fetoprotein mRNA levels in peripheral blood of patients with hepatocellular carcinoma: a predictor of postoperative recurrence or metastasis?
    Zhang Y; Song T; Meng L; Wu X; Ba Y; Li Q
    ANZ J Surg; 2009; 79(1-2):62-9. PubMed ID: 19183381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the first site of relapse for cancerous tumors using protein expression profiles.
    Engh JA
    Neurosurgery; 2011 Dec; 69(6):N10-2. PubMed ID: 22067341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.